ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Allogene Therapeutics Inc

Allogene Therapeutics Inc (ALLO)

2.18
0.16
(7.92%)
Cerrado 08 Marzo 3:00PM
2.19
0.01
(0.46%)
Fuera de horario: 6:53PM

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Estadísticas y detalles clave

Último Precio
2.19
Postura de Compra
2.19
Postura de Venta
2.29
Volume Operado de la Acción
4,702,232
2.04 Rango del Día 2.32
1.32 Rango de 52 semanas 5.775
Capitalización de Mercado [m]
Precio Anterior
2.02
Precio de Apertura
2.05
Última hora de negociación
Volumen financiero
US$ 10,362,810
Precio Promedio Ponderado
2.2038
Volumen promedio (3 m)
5,547,169
Acciones en circulación
209,672,091
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-1.40
Beneficio por acción (BPA)
-1.56
turnover
95k
Beneficio neto
-327.27M

Acerca de Allogene Therapeutics Inc

Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple all... Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies. Mostrar más

Sector
Biological Pds,ex Diagnstics
Industria
Biological Pds,ex Diagnstics
Sitio web
Sede
Wilmington, Delaware, USA
Fundado
-
Allogene Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ALLO. The last closing price for Allogene Therapeutics was US$2.02. Over the last year, Allogene Therapeutics shares have traded in a share price range of US$ 1.32 to US$ 5.775.

Allogene Therapeutics currently has 209,672,091 shares in issue. The market capitalisation of Allogene Therapeutics is US$423.54 million. Allogene Therapeutics has a price to earnings ratio (PE ratio) of -1.40.

ALLO Últimas noticias

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.2814.65968586391.912.31.6936441761.91428469CS
40.5836.02484472051.613.781.32104429892.36567351CS
120.167.881773399012.033.781.3255471692.23040478CS
26-0.22-9.128630705392.413.781.3236900002.3629694CS
52-3.51-61.57894736845.75.7751.3230652672.64458816CS
156-6.08-73.51874244268.2717.491.3224347084.9698028CS
260-23.21-91.377952755925.4551.3219129199.91821744CS

ALLO - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Allogene Therapeutics?
El precio actual de las acciones de Allogene Therapeutics es US$ 2.19
¿Cuántas acciones de Allogene Therapeutics están en circulación?
Allogene Therapeutics tiene 209,672,091 acciones en circulación
¿Cuál es la capitalización de mercado de Allogene Therapeutics?
La capitalización de mercado de Allogene Therapeutics es USD 423.54M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Allogene Therapeutics?
Allogene Therapeutics ha negociado en un rango de US$ 1.32 a US$ 5.775 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Allogene Therapeutics?
El ratio precio/beneficio de Allogene Therapeutics es -1.4
¿Cuál es el ratio de efectivo a ventas de Allogene Therapeutics?
El ratio de efectivo a ventas de Allogene Therapeutics es 4.36k
¿Cuál es la moneda de reporte de Allogene Therapeutics?
Allogene Therapeutics presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Allogene Therapeutics?
El último ingresos anual de Allogene Therapeutics es USD 95k
¿Cuál es el último beneficio anual de Allogene Therapeutics?
El último beneficio anual de Allogene Therapeutics es USD -327.27M
¿Cuál es la dirección registrada de Allogene Therapeutics?
La dirección registrada de Allogene Therapeutics es 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
¿Cuál es la dirección del sitio web de Allogene Therapeutics?
La dirección del sitio web de Allogene Therapeutics es www.allogene.com
¿En qué sector industrial opera Allogene Therapeutics?
Allogene Therapeutics opera en el sector BIOLOGICAL PDS,EX DIAGNSTICS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
ABLVAble View Global Inc
US$ 1.73
(137.18%)
5.14M
SUNESUNation Energy Inc
US$ 0.402999
(127.55%)
482.05M
BTOGBit Origin Ltd
US$ 0.6117
(118.46%)
622.67M
DWTXDogwood Therapeutics Inc
US$ 6.63
(49.66%)
25.92M
KZIAKazia Therapeutics Ltd
US$ 1.1899
(40.80%)
4.5M
ALBTAvalon GloboCare Corporation
US$ 6.96
(-36.15%)
577.55k
SCNXScienture Holdings Inc
US$ 1.55
(-35.68%)
1.59M
ACXPAcurx Pharmaceuticals Inc
US$ 0.4572
(-29.88%)
1.18M
RETOReTo Eco Solutions Inc
US$ 5.42
(-27.73%)
108.27k
OCTOEightco Holdings Inc
US$ 1.08
(-27.03%)
336.99k
BTOGBit Origin Ltd
US$ 0.6117
(118.46%)
622.67M
SUNESUNation Energy Inc
US$ 0.402999
(127.55%)
482.05M
NVDANVIDIA Corporation
US$ 112.69
(1.92%)
341.94M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 10.675
(-0.70%)
143.04M
ICONIcon Energy Corporation
US$ 0.169898
(17.17%)
142.23M

ALLO Discussion

Ver más
glenn1919 glenn1919 3 semanas hace
ALLO.............................................https://stockcharts.com/h-sc/ui?s=ALLO&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 3 semanas hace
ALLO...............................https://stockcharts.com/h-sc/ui?s=ALLO&p=W&b=5&g=0&id=p86431144783
👍️0
georgie18 georgie18 2 meses hace
ALLO...$2.35...🥳...Nice move off the $1.80 Range Bottom...

georgie18

Member Level
Re: georgie18 post# 387047

Thursday, January 02, 2025 9:51:39 AM

Post#
387852
of 388270
ALLO...$2.20s clearing here...🥳

georgie18

Member Level
Re: georgie18 post# 667756

Monday, December 16, 2024 2:11:12 PM

Post#
667880
of 670030
ALLO...$2.08...🥳...Reversal Candle off the $1.80 range bottom...

georgie18

Member Level
Re: georgie18 post# 385710

Friday, December 13, 2024 2:38:52 PM

Post#
386948
of 387046
ALLO...$1.85...🥳Look like tax selling to me...Scooping up the dip...

georgie18

Member Level
Re: georgie18 post# 664158

Friday, November 15, 2024 11:35:10 AM

Post#
665142
of 667755
ALLO...$2.35...Bottoming out here...🥳They have 400 Million cash reserve...get them through mid 2026...
👍️0
georgie18 georgie18 2 meses hace
ALLO...$2.20s clearing here...🥳

georgie18

Member Level
Re: georgie18 post# 667756

Monday, December 16, 2024 2:11:12 PM

Post#
667880
of 670030
ALLO...$2.08...🥳...Reversal Candle off the $1.80 range bottom...

georgie18

Member Level
Re: georgie18 post# 385710

Friday, December 13, 2024 2:38:52 PM

Post#
386948
of 387046
ALLO...$1.85...🥳Look like tax selling to me...Scooping up the dip...

georgie18

Member Level
Re: georgie18 post# 664158

Friday, November 15, 2024 11:35:10 AM

Post#
665142
of 667755
ALLO...$2.35...Bottoming out here...🥳They have 400 Million cash reserve...get them through mid 2026...
👍️0
Monksdream Monksdream 3 meses hace
ALLO under $2
👍️0
georgie18 georgie18 3 meses hace
ALLO...$2.08...🥳...Reversal Candle off the $1.80 range bottom...

georgie18

Member Level
Re: georgie18 post# 385710

Friday, December 13, 2024 2:38:52 PM

Post#
386948
of 387046
ALLO...$1.85...🥳Look like tax selling to me...Scooping up the dip...

georgie18

Member Level
Re: georgie18 post# 664158

Friday, November 15, 2024 11:35:10 AM

Post#
665142
of 667755
ALLO...$2.35...Bottoming out here...🥳They have 400 Million cash reserve...get them through mid 2026...
👍️0
georgie18 georgie18 3 meses hace
ALLO...$1.85...🥳Look like tax selling to me...Scooping up the dip...

georgie18

Member Level
Re: georgie18 post# 664158

Friday, November 15, 2024 11:35:10 AM

Post#
665142
of 667755
ALLO...$2.35...Bottoming out here...🥳They have 400 Million cash reserve...get them through mid 2026...
👍️0
georgie18 georgie18 4 meses hace
ALLO...$2.35...Bottoming out here...🥳They have 400 Million cash reserve...get them through mid 2026...
👍️0
georgie18 georgie18 4 meses hace
Have a Great Weekend Y'all...🥳
👍️0
georgie18 georgie18 4 meses hace
ALLO...$3.19...🥳...https://finance.yahoo.com/news/allogene-therapeutics-inc-allo-q3-110724066.html
👍️0
georgie18 georgie18 4 meses hace
ALLO...$3.31...Fins after todays close...🥳

georgie18

Member Level
Re: georgie18 post# 385280

Wednesday, November 06, 2024 10:27:01 AM

Post#
385286
of 385334
ALLO...$3.22s clearing here...🥳...Looking for the $5.78 Breakout... https://schrts.co/wITCFkcf

georgie18

Member Level
Re: georgie18 post# 663758

Wednesday, November 06, 2024 10:06:32 AM

Post#
663791
of 663807
ALLO...$3.17...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 385240

Wednesday, November 06, 2024 7:12:20 AM

Post#
385251
of 385279
ALLO...$3.10...🥳

georgie18

Member Level
Re: georgie18 post# 663652

Tuesday, November 05, 2024 3:37:32 PM

Post#
663738
of 663757
ALLO...$3 ...starting up again...🥳

georgie18

Member Level
Re: georgie18 post# 385217

Tuesday, November 05, 2024 9:15:04 AM

Post#
385226
of 385239
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product
Ongoing Phase 1 Data Supported the FDA's Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC Therapies
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.
👍️0
georgie18 georgie18 4 meses hace
ALLO...$3.22s clearing here...🥳...Looking for the $5.78 Breakout... https://schrts.co/wITCFkcf

georgie18

Member Level
Re: georgie18 post# 663758

Wednesday, November 06, 2024 10:06:32 AM

Post#
663791
of 663807
ALLO...$3.17...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 385240

Wednesday, November 06, 2024 7:12:20 AM

Post#
385251
of 385279
ALLO...$3.10...🥳

georgie18

Member Level
Re: georgie18 post# 663652

Tuesday, November 05, 2024 3:37:32 PM

Post#
663738
of 663757
ALLO...$3 ...starting up again...🥳

georgie18

Member Level
Re: georgie18 post# 385217

Tuesday, November 05, 2024 9:15:04 AM

Post#
385226
of 385239
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product
Ongoing Phase 1 Data Supported the FDA's Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC Therapies
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.
👍️0
georgie18 georgie18 4 meses hace
ALLO...$3.17...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 385240

Wednesday, November 06, 2024 7:12:20 AM

Post#
385251
of 385279
ALLO...$3.10...🥳

georgie18

Member Level
Re: georgie18 post# 663652

Tuesday, November 05, 2024 3:37:32 PM

Post#
663738
of 663757
ALLO...$3 ...starting up again...🥳

georgie18

Member Level
Re: georgie18 post# 385217

Tuesday, November 05, 2024 9:15:04 AM

Post#
385226
of 385239
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product
Ongoing Phase 1 Data Supported the FDA's Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC Therapies
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.
👍️0
georgie18 georgie18 4 meses hace
ALLO...$3.10...🥳

georgie18

Member Level
Re: georgie18 post# 663652

Tuesday, November 05, 2024 3:37:32 PM

Post#
663738
of 663757
ALLO...$3 ...starting up again...🥳

georgie18

Member Level
Re: georgie18 post# 385217

Tuesday, November 05, 2024 9:15:04 AM

Post#
385226
of 385239
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product
Ongoing Phase 1 Data Supported the FDA's Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC Therapies
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.
👍️0
georgie18 georgie18 4 meses hace
ALLO...$3 ...starting up again...🥳

georgie18

Member Level
Re: georgie18 post# 385217

Tuesday, November 05, 2024 9:15:04 AM

Post#
385226
of 385239
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product
Ongoing Phase 1 Data Supported the FDA's Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC Therapies
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.
👍️0
georgie18 georgie18 4 meses hace
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product
Ongoing Phase 1 Data Supported the FDA's Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC Therapies
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.
👍️0
georgie18 georgie18 4 meses hace
ALLO...$3...Hitting again...🥳

georgie18

Member Level
Re: None

Wednesday, October 30, 2024 10:54:12 AM

Post#
385056
of 385216
ALLO...$2.93..."W" in play here... https://schrts.co/BrIJNzMB ...Financials will be announced on the 7th of November...28% short...insiders own 34%...Float 138 million...
👍️0
georgie18 georgie18 4 meses hace
ALLO...$2.93..."W" in play here... https://schrts.co/BrIJNzMB ...Financials will be announced on the 7th of November...28% short...insiders own 34%...Float 138 million...
👍️0
TrendTrade2016 TrendTrade2016 4 meses hace
ALLO BIO BEASTING
👍️0
Monksdream Monksdream 5 meses hace
ALLO under $3
👍️0
Mactheriverrat Mactheriverrat 5 meses hace
ALLO coiled to run
👍️0
georgie18 georgie18 5 meses hace
ALLO...$3 Hitting again...🥳

georgie18

Member Level
Re: georgie18 post# 41

Friday, September 27, 2024 3:57:49 PM

Post#
42
of 42
ALLO...$2.90...Setting up for the $3 Break again...🥳

georgie18

Member Level
Re: georgie18 post# 658272

Wednesday, September 25, 2024 10:03:06 AM

Post#
659219
of 659662
ALLO...$2.65...added more here on the dip...🥳

georgie18

Member Level
Re: None

Wednesday, September 18, 2024 1:30:50 PM

Post#
40
of 40
ALLO...$2.79 added the dip ...🥳
👍️0
georgie18 georgie18 5 meses hace
ALLO...$2.90...Setting up for the $3 Break again...🥳

georgie18

Member Level
Re: georgie18 post# 658272

Wednesday, September 25, 2024 10:03:06 AM

Post#
659219
of 659662
ALLO...$2.65...added more here on the dip...🥳

georgie18

Member Level
Re: None

Wednesday, September 18, 2024 1:30:50 PM

Post#
40
of 40
ALLO...$2.79 added the dip ...🥳
👍️0
georgie18 georgie18 5 meses hace
ALLO...$2.65...added more here on the dip...🥳

georgie18

Member Level
Re: None

Wednesday, September 18, 2024 1:30:50 PM

Post#
40
of 40
ALLO...$2.79 added the dip ...🥳
👍️0
georgie18 georgie18 6 meses hace
ALLO...$2.79 added the dip ...🥳
👍️0
georgie18 georgie18 6 meses hace
ALLO...$2.98...W pattern still in play here...Looking for $3.23 Break...🥳off the $2.55 alert...

georgie18

Member Level
Re: georgie18 post# 36

Wednesday, September 11, 2024 4:02:04 PM

Post#
38
of 38
ALLO...$2.92...Psar flipped Bullish...Trying for upper bollie break...🥳...

georgie18

Member Level
Re: georgie18 post# 652456

Monday, August 26, 2024 2:22:57 PM

Post#
655267
of 657175
ALLO...$2.79...Off my $2.55...Alert...Still looking for $3 Break...🥳

georgie18

Member Level
Re: georgie18 post# 32

Thursday, August 22, 2024 9:38:16 AM

Post#
33
of 35
ALLO...$2.72s clearing here...🥳

georgie18

Member Level
Re: georgie18 post# 652456

Monday, August 19, 2024 3:08:16 PM

Post#
654171
of 654707
ALLO...$2.60s clearing here...🥳

georgie18

Member Level
Re: None

Tuesday, August 06, 2024 1:20:27 PM

Post#
382404
of 382735
ALLO...$2.55s starting here...coming off the bottom...🥳
👍️0
georgie18 georgie18 6 meses hace
ALLO...$2.92...Psar flipped Bullish...Trying for upper bollie break...🥳...

georgie18

Member Level
Re: georgie18 post# 652456

Monday, August 26, 2024 2:22:57 PM

Post#
655267
of 657175
ALLO...$2.79...Off my $2.55...Alert...Still looking for $3 Break...🥳

georgie18

Member Level
Re: georgie18 post# 32

Thursday, August 22, 2024 9:38:16 AM

Post#
33
of 35
ALLO...$2.72s clearing here...🥳

georgie18

Member Level
Re: georgie18 post# 652456

Monday, August 19, 2024 3:08:16 PM

Post#
654171
of 654707
ALLO...$2.60s clearing here...🥳

georgie18

Member Level
Re: None

Tuesday, August 06, 2024 1:20:27 PM

Post#
382404
of 382735
ALLO...$2.55s starting here...coming off the bottom...🥳
👍️0
Monksdream Monksdream 6 meses hace
ALLO under $3

👍️0
georgie18 georgie18 6 meses hace
ALLO...$2.79...Off my $2.55...Alert...Still looking for $3 Break...🥳

georgie18

Member Level
Re: georgie18 post# 32

Thursday, August 22, 2024 9:38:16 AM

Post#
33
of 35
ALLO...$2.72s clearing here...🥳

georgie18

Member Level
Re: georgie18 post# 652456

Monday, August 19, 2024 3:08:16 PM

Post#
654171
of 654707
ALLO...$2.60s clearing here...🥳

georgie18

Member Level
Re: None

Tuesday, August 06, 2024 1:20:27 PM

Post#
382404
of 382735
ALLO...$2.55s starting here...coming off the bottom...🥳
👍️0
georgie18 georgie18 6 meses hace
Thanks for posting...🥳
👍️0
glens0 glens0 6 meses hace
ALLO Current Institutional Ownership Percentage 83.63% up from 63%
187 Institutional Holders 165,517,865 Total Shares Held
https://www.marketbeat.com/stocks/NASDAQ/ALLO/institutional-ownership/
👍️0
georgie18 georgie18 6 meses hace
ALLO...$2.72s clearing here...🥳

georgie18

Member Level
Re: georgie18 post# 652456

Monday, August 19, 2024 3:08:16 PM

Post#
654171
of 654707
ALLO...$2.60s clearing here...🥳

georgie18

Member Level
Re: None

Tuesday, August 06, 2024 1:20:27 PM

Post#
382404
of 382735
ALLO...$2.55s starting here...coming off the bottom...🥳
👍️0
georgie18 georgie18 7 meses hace
ALLO...$2.60s clearing here...🥳

georgie18

Member Level
Re: None

Tuesday, August 06, 2024 1:20:27 PM

Post#
382404
of 382735
ALLO...$2.55s starting here...coming off the bottom...🥳
👍️0
georgie18 georgie18 7 meses hace
ALLO...$2.55s starting here...coming off the bottom...🥳
👍️0
Monksdream Monksdream 7 meses hace
ALLO under $3
👍️0
Monksdream Monksdream 9 meses hace
ALLO under $3
👍️0
Monksdream Monksdream 10 meses hace
ALLO under $3
👍️0
Monksdream Monksdream 1 año hace
ALLO new 52 week low
👍️0
NY1972 NY1972 1 año hace
Yes. Signet-ring, TP53. ... dying. Even more aggressive than the ones enrolled in CART trial
👍️0
jondoeuk jondoeuk 1 año hace
Was that the case study (50-year-old female)?

I know the CAR-T is already in registrational trials both in China and the US. If all goes to plan, they expected to submit an NDA to the NMPA in 2024 and a BLA to the FDA in 2025. A next-gen version is in the clinic as well https://aacrjournals.org/clincancerres/article/26/20/5494/82735/Coexpression-of-IL7-and-CCL21-Increases-Efficacy

Also https://www.biospace.com/article/moderna-carsgen-join-forces-combining-mrna-cancer-vaccine-with-car-t/

However, it's getting pretty crowded
👍️0
NY1972 NY1972 1 año hace
https://x.com/ny1972_47/status/1707238076190175679?s=20
👍️0
jondoeuk jondoeuk 1 año hace
Upcoming https://www.globenewswire.com/news-release/2023/09/27/2750477/0/en/Allogene-Therapeutics-Announces-Three-Poster-Presentations-from-its-Next-Generation-AlloCAR-T-Platform-at-the-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting.html
👍️0
dmerc dmerc 2 años hace
short 49% Mentioned by Roensche Capital
👍️0
dmerc dmerc 2 años hace
https://www.benzinga.com/quote/ALLO/analyst-ratings
👍️0
jondoeuk jondoeuk 2 años hace
An oral presentation at AACR next month https://www.abstractsonline.com/pp8/#!/10828/presentation/10251
👍️0
jondoeuk jondoeuk 2 años hace
A proprietary approach to control rejection https://www.globenewswire.com/news-release/2022/11/10/2553356/0/en/Allogene-Therapeutics-Unveils-Novel-Approach-to-Generate-Engineered-AlloCAR-T-Cells-to-Control-Immune-Rejection-at-the-Annual-Meeting-of-the-Society-for-Immunotherapy-of-Cancer.html

This is one of a number of next-gen technologies being pioneered. Others, include https://www.globenewswire.com/en/news-release/2023/02/01/2599947/0/en/Allogene-Therapeutics-Presents-Data-on-Dagger-a-Next-Generation-AlloCAR-T-Platform-Technology.html
👍️0
jondoeuk jondoeuk 2 años hace
R&D showcase PR https://www.globenewswire.com/news-release/2022/11/29/2564467/0/en/Allogene-Therapeutics-R-D-Showcase-Features-Hematologic-and-Solid-Tumor-Advances-Across-its-AlloCAR-T-Platform.html

Slides https://ir.allogene.com/static-files/3eacf8bf-3cd0-47bc-a5ac-f5715083883a
👍️0
jondoeuk jondoeuk 3 años hace
ASGCT PR https://www.globenewswire.com/news-release/2022/05/19/2446950/0/en/Allogene-Therapeutics-Announces-Oral-Presentation-of-Pre-Clinical-Data-Highlighting-Improved-Anti-Tumor-Activity-of-Donor-Derived-Allogeneic-CAR-T-Cells-at-American-Society-of-Gene.html
👍️0
jondoeuk jondoeuk 3 años hace
New preclinical data https://aacrjournals.org/cancerrescommun/article/2/3/158/684708/Allogeneic-Anti-BCMA-CAR-T-Cells-Are-Superior-to
👍️0
jondoeuk jondoeuk 3 años hace
Additional data https://allogene.com/resources/download/ALPHA-Study.pdf https://allogene.com/resources/download/ALPHA2-Study.pdf https://allogene.com/resources/download/UNIVERSAL-Updated-Phase-1-Data-Validates-Feasibility-Allogeneic.pdf
https://ir.allogene.com/static-files/891ef05d-ff61-4c95-9a55-9ff7a515102d
👍️0

Su Consulta Reciente

Delayed Upgrade Clock